IVVDInvivyd, Inc.同业对比
Invivyd, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IVVD本股 | $224M#8 | — | 1.2x#2 | 4.2x#2 | 110.5%#3 | 69.1%#5 | -104.0%#3 | -29.0%#6 | — | — | -39.2%#13 | — |
| INKT | $59M#12 | — | — | — | — | -15.9%#11 | — | — | — | — | -19.0%#9 | — |
| INMB | $65M#11 | — | 3.2x#7 | 1304.4x#8 | 257.1%#2 | -9.5%#10 | -94766.0%#8 | -225.9%#12 | -607.3%#4 | — | 19.3%#7 | — |
| INTS | $13M#14 | — | 1.4x#4 | — | — | 28.7%#8 | — | -126.0%#11 | — | — | -36.6%#12 | — |
| IOVA | $4.6B#3 | — | 6.3x#9 | 17.6x#3 | 60.6%#4 | -5.1%#9 | -153.1%#4 | -53.1%#7 | — | — | 365.9%#1 | — |
| IPHA | $180M#9 | — | — | — | — | — | — | — | — | — | -4.0%#8 | — |
| IPSC | $333M#6 | — | 1.4x#5 | 3.1x#1 | 1556.8%#1 | 92.4%#4 | -15.8%#2 | -4.1%#5 | -9.3%#2 | — | 269.3%#2 | — |
| JSPR | $21M#13 | — | 14.8x#12 | — | — | 100.0%#2 | — | -0.0%#3 | — | — | -75.7%#14 | — |
| JSPRW | $296144#15 | — | 0.2x#1 | — | — | 100.0%#2 | — | -0.0%#3 | — | — | -91.1%#15 | — |
| KLRS | $75M#10 | — | 1.3x#3 | 455.9x#7 | — | 37.2%#7 | -27970.9%#7 | -75.3%#8 | — | — | -28.5%#10 | — |
| KOD | $2.1B#4 | — | 33.6x#13 | — | — | -30.5%#13 | — | -376.4%#13 | — | — | 232.3%#3 | — |
| KRYS | $10.0B#1 | 42.2x#1 | 7.3x#11 | 25.6x#5 | 33.9%#6 | 129.7%#1 | 41.5%#1 | 15.1%#2 | 17.2%#1 | — | 109.8%#5 | — |
| KYMR | $9.8B#2 | — | 6.5x#10 | 249.8x#6 | -16.7%#7 | 39.1%#6 | -891.1%#6 | 20.6%#1 | — | — | 130.3%#4 | — |
| KYTX | $441M#5 | — | 2.7x#6 | — | — | -26.5%#12 | — | -97.4%#9 | -107.1%#3 | — | 41.9%#6 | — |
| LCTX | $259M#7 | — | 4.3x#8 | 17.8x#4 | 53.2%#5 | -241.4%#14 | -251.6%#5 | -104.3%#10 | — | — | -33.4%#11 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-19。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议